Applications for nitric oxide in halting proliferation of tumor cells

Melissa M Reynolds1, Scott D Witzeling, Vinod B Damodaran

  • 1Department of Chemistry, Colorado State University, Fort Collins, CO 80523-1052, USA.

Insights

Nitric oxide (NO) can sensitize tumors to chemotherapy and radiation, overcoming treatment resistance. NO donors also show potential for independent cancer treatment, offering new therapeutic avenues.

Area of Science:

  • Oncology
  • Medical Chemistry
  • Cancer Biology

Background:

  • Tumor resistance to cytotoxic therapies presents a significant challenge in cancer treatment.
  • Dose-limiting toxicities of conventional therapies restrict their efficacy.
  • Nitric oxide (NO) is emerging as a key molecule in cancer therapeutics.

Purpose of the Study:

  • To explore the role of nitric oxide in overcoming tumor resistance.
  • To discuss the potential of nitric oxide donors as adjuncts to conventional cancer treatments.
  • To evaluate the independent therapeutic potential of nitric oxide donors in cancer management.

Main Methods:

  • Literature review on nitric oxide's role in cancer.
  • Analysis of studies on nitric oxide donors in combination therapy.
  • Examination of evidence for nitric oxide donors as standalone treatments.

Main Results:

  • Nitric oxide enhances tumor sensitization to chemotherapy and radiotherapy.
  • Nitric oxide donors demonstrate potential as adjuvant therapies.
  • Emerging data suggest independent anti-cancer activity of nitric oxide donors.

Conclusions:

  • Nitric oxide is a promising agent for improving the effectiveness of existing cancer treatments.
  • Nitric oxide donors represent a viable strategy to overcome therapeutic resistance.
  • Further research into nitric oxide-based therapies could revolutionize cancer care.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...